Ibgliptin-M 1000 Tablet SR is a combination oral antidiabetic medication containing Metformin 1000 mg and Teneligliptin 20 mg, designed for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of incretin hormones such as GLP-1 and GIP, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner. The sustained-release formulation of Ibgliptin-M 1000 ensures prolonged therapeutic plasma concentrations, promoting better compliance and stable glycemic control throughout the day. This combination therapy is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target blood glucose levels. It is essential to monitor renal function periodically, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Teneligliptin is generally well tolerated with a low risk of hypoglycemia when used as prescribed. Ibgliptin-M 1000 Tablet SR should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.